Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust) Versus Herceptin® in Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03425656
Recruitment Status : Completed
First Posted : February 7, 2018
Last Update Posted : July 10, 2020
Sponsor:
Information provided by (Responsible Party):
AryoGen Pharmed Co.

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Completed
Actual Primary Completion Date : March 6, 2018
Actual Study Completion Date : August 5, 2018